Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,399 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 3,399 · Balance 3,399 F1: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2: Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F2: Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 9,098 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 580,809 · Balance 9,098 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $118.83 · Expires 2027-03-27 | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-21 · Disposition to issuer · Disposed 56,762 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 16,146 · Balance 0 F1: Includes 3,695 restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. F2: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.54 · Expires 2028-11-21 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 2,012 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.81 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 6,523 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.36 · Expires 2030-03-05 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 7,322 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.03 · Expires 2031-03-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 5,055 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.28 · Expires 2032-03-10 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 5,293 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.49 · Expires 2033-03-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 4,210 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.32 · Expires 2034-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 4,536 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F4: For Footnote (4), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 3,695 restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan.
F2: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F3: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F4: For Footnote (4), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 21:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 3,399 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000246 · edgardoc.xml · derivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,399 Underlying: Common Stock · 3,399 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · derivative.exercise_date: Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026. F2 · derivative.expiration_date: Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:59 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,753 | $0.00 Strike: $75.13 | $0.00 |
DisclosureSEC source: 0000874015-26-000202 · edgardoc.xml · derivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,753 Underlying: Common Stock · 10,753 shares Expires 2036-06-04 F1 · derivative.exercise_date: Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026. F1 · derivative.expiration_date: Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | Not disclosed Strike: $64.36 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 9 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 4,536 | Not disclosed Strike: $76.32 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 8 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,536 shares Expires 2034-03-07 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 4,210 | Not disclosed Strike: $78.49 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 7 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,210 shares Expires 2033-03-09 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,293 | Not disclosed Strike: $70.28 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 6 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,293 shares Expires 2032-03-10 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,055 | Not disclosed Strike: $71.03 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 5 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,055 shares Expires 2031-03-11 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 7,322 | Not disclosed Strike: $47.36 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 4 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,322 shares Expires 2030-03-05 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 6,523 | Not disclosed Strike: $46.81 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 3 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,523 shares Expires 2029-03-07 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 2,012 | Not disclosed Strike: $41.54 | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,012 shares Expires 2028-11-21 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:06 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerCommon Stock | 16,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000063 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 3,695 restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3 · price: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:17 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 3,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000019 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,146 F1 · shares: Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 3,695 restricted stock units, the settlement of which have been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:18 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | $0.00 Strike: $64.36 | $0.00 |
DisclosureSEC source: 0001127602-25-007242 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,535 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F4 · derivative.exercise_date: Options become exercisable on the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:18 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007242 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,956 F1 · shares: Represents restricted stock units which vest on the date of the 2026 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 3,695 restricted stock units, the settlement of which have been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:54 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,536 | $0.00 Strike: $76.32 | $0.00 |
DisclosureSEC source: 0001127602-24-009440 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,536 Underlying: Common Stock · 4,536 shares Expires 2034-03-07 F4 · derivative.exercise_date: Options become exercisable on the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:54 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009440 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,092 F1 · shares: Represents restricted stock units which vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 3,695 restricted stock units, the settlement of which have been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 20:16 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,210 | $0.00 Strike: $78.49 | $0.00 |
DisclosureSEC source: 0001127602-23-009870 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,210 Underlying: Common Stock · 4,210 shares Expires 2033-03-09 F4 · derivative.exercise_date: Options become exercisable on the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 20:16 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009870 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,520 F1 · kind: Represents restricted stock units which vest on the date of the 2024 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 3,695 restricted stock units, the settlement of which have been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:26 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,293 | $0.00 Strike: $70.28 | $0.00 |
DisclosureSEC source: 0001127602-22-009136 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,293 Underlying: Common Stock · 5,293 shares Expires 2032-03-10 F4 · derivative.exercise_date: Options become exercisable on the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:26 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009136 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,055 F1 · shares: Represents restricted stock units which vest on the date of the 2023 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 3,695 restricted stock units, the settlement of which have been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:32 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerOption to Purchase Common Stock · Derivative | 56,762 | $118.83 Strike: $118.83 | $6,745,028.46 |
DisclosureSEC source: 0000899866-21-000063 · wf-form4_162707230143608.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 56,762 shares Expires 2027-03-27 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:32 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerCommon Stock, par value $.0001 per share | 580,809 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000063 · wf-form4_162707230143608.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,098 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 16:56 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 119,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000058 · wf-form4_162646894566541.xml · nonDerivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,907 F2 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 16:56 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 120,894 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000058 · wf-form4_162646894566541.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,060 F1 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan. Read SEC document |
| March 29, 2021 Filed Apr 1, 2021 07:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 2,332 | $154.03 | $359,197.96 |
DisclosureSEC source: 0000899866-21-000030 · wf-form4_161727741953647.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,166 F1 · kind: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 22:16 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,055 | $0.00 Strike: $71.03 | $0.00 |
DisclosureSEC source: 0001127602-21-010626 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,055 Underlying: Common Stock · 5,055 shares Expires 2031-03-11 F4 · derivative.exercise_date: Option becomes exercisable on the date of the 2022 Annual Meeting of Stockholders. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 22:16 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010626 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,490 F1 · shares: Represents restricted stock units which vest on the date of the 2022 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F3 · balance_after: Includes 2,217 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 18:01 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 83,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000029 · wf-form4_161472605260522.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,498 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:12 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 13,059 | $157.96 | $2,062,799.64 |
DisclosureSEC source: 0000899866-20-000097 · wf-form4_160832951612396.xml · nonDerivative · entry 3 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,773 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:12 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 72,533 | $157.96 | $11,457,312.68 |
DisclosureSEC source: 0000899866-20-000097 · wf-form4_160832951612396.xml · nonDerivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,832 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:12 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 162,707 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000097 · wf-form4_160832951612396.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,365 F1 · shares: Shares acquired on vesting of Performance Stock Units previously granted on February 28, 2018 under the 2017 Stock Incentive Plan. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 17:04 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 3,202 | $85.43 | $273,546.86 |
DisclosureSEC source: 0000899866-20-000035 · wf-form4_158568864459640.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,658 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,322 | $0.00 Strike: $47.36 | $0.00 |
DisclosureSEC source: 0001127602-20-009972 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,322 Underlying: Common Stock · 7,322 shares Expires 2030-03-05 F3 · derivative.exercise_date: Options become exercisable on the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009972 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,012 F1 · shares: Represents restricted stock units which vest on the date of the 2021 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 18:30 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 8,406 | $90.54 | $761,079.24 |
DisclosureSEC source: 0000899866-20-000025 · wf-form4_158327818642994.xml · nonDerivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,860 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.26. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:30 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 44,201 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000025 · wf-form4_158327818642994.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,266 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 17:00 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 12,771 | $102.97 | $1,315,029.87 |
DisclosureSEC source: 0000899866-20-000016 · wf-form4_158137198557055.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,065 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $102.97 - $103.19. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 20:31 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,523 | $0.00 Strike: $46.81 | $0.00 |
DisclosureSEC source: 0001127602-19-010811 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,523 Underlying: Common Stock · 6,523 shares Expires 2029-03-07 F3 · derivative.exercise_date: Options become exercisable on the date of the 2020 Annual Meeting of Stockholders Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 20:31 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-010811 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,795 F1 · shares: Represents restricted stock units which vest on the date of the 2020 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:39 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 4,043 | $132.92 | $537,395.56 |
DisclosureSEC source: 0000899866-19-000039 · wf-form4_155173914470163.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,638 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $134.70. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 20:24 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 37,198 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-19-000052 · wf-form4_155183546915912.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,836 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 18:39 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 13,015 | $119.57 | $1,556,203.55 |
DisclosureSEC source: 0000899866-19-000016 · wf-form4_154992834912908.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,681 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $119.42 - $119.57. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 18:07 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 3,244 | $95.85 | $310,937.40 |
DisclosureSEC source: 0000899866-19-000005 · wf-form4_154655683354052.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,696 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $95.84 - $96.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:15 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 2,012 | $0.00 Strike: $41.54 | $0.00 |
DisclosureSEC source: 0001127602-18-034295 · form4.xml · derivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,012 Underlying: Common Stock · 2,012 shares Expires 2028-11-21 F3 · derivative.exercise_date: Options become exercisable on the date of the 2019 Annual Meeting of Stockholders. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:15 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-034295 · form4.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659 F1 · shares: Represents restricted stock units which vest on the date of the 2019 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:01 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 35,760 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000061 · wf-form4_152002808052042.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,940 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 08, 2018 Filed Feb 8, 2018 19:16 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 13,245 | $116.31 | $1,540,525.95 |
DisclosureSEC source: 0000899866-18-000036 · wf-form4_151813535338397.xml · nonDerivative · entry 2 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,180 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.00 - $116.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 19:16 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 95,253 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000036 · wf-form4_151813535338397.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,425 F1 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 95,253 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 18:33 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 2,553 | $121.63 | $310,521.39 |
DisclosureSEC source: 0000899866-18-000002 · wf-form4_151510879943504.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,172 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $121.00 - $121.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| June 14, 2017 Filed Jun 19, 2017 17:21 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | PurchaseCommon Stock, par value $.0001 per share | 10,000 | $116.72 | $1,167,200.00 |
DisclosureSEC source: 0000899866-17-000144 · wf-form4_149790725629978.xml · nonDerivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,725 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.